Infectious disease
The retooled COVID-19 vaccine promised by GlaxoSmithKline and vaccine giant Sanofi is entering Phase IIb testing, with new antigen dosages it hopes will boost the lackluster immune response seen in adults 50 and over during its last Phase I/II trial.
There’s plenty of COVID-19-related news today. Here’s a look.
The vaccine will be manufactured and distributed around the world by Novavax and Serum Institute of India (SII).
Shares in the company shot up 212.6% following the news it had isolated the potentially variant-neutralizing antibodies.
An open letter from a group of academics is urging the Biden administration to implement updates to guidance and standards that will better protect high-risk workers from the novel coronavirus that causes coronavirus disease 2019 (COVID-19).
With distribution of COVID-19 vaccines being slow, public health officials and researchers are trying to develop schemes and rationales for delaying the dosing of the second shots.
Several mutations of the SARS-CoV-2 virus that causes COVID-19, which are being called variants, are increasingly being found around the world.
Currently, research is still ongoing with regards to the link between COVID and POTS. However, this increasing number of cases and the unfamiliarity of COVID’s long-lasting effects leave a lot more for the researchers to unmask.
COVID-19 reinfections are occurring but, so far, scientists don’t have all the details.
With the COVID-19 vaccine rollout underway and a renewed sense of hope stemming from an aggressive vaccine dispersal plan, a common question has begun to emerge.
PRESS RELEASES